In our last post we covered adhesion: the dense, stuck-together, scar-like tissue that can form in overused or underused muscle and change how force moves through a joint. There is a second piece that rarely comes up outside research circles. It is called cellular senescence, and research on fibrosis suggests it may be tangled up with adhesion.
What senescence is
Most cells can divide only a limited number of times before they hit an internal stop sign. When a cell reaches that limit, or is damaged by injury, inflammation, or mechanical stress, it does not necessarily die. It can switch into senescence: alive, but permanently unable to divide. Researchers sometimes call these "zombie cells." A senescent cell is not quiet. It secretes a mix of inflammatory signals, enzymes, and growth factors called the senescence-associated secretory phenotype (SASP). That mix spreads outward and affects the healthy tissue around it.
How senescent cells drive fibrosis
The SASP is where senescence and fibrosis connect. It includes enzymes that break down the existing structure of connective tissue. It also includes signaling molecules, chiefly a growth factor called TGF-β, that push nearby cells to lay down excess, disorganized collagen in its place. A 2025 review in the journal Aging and Disease on tissue fibrosis and cellular senescence describes the result: tissue that trades organized, flexible structure for dense, stiff, scar-like material. That is close to how we describe adhesion.
The relationship appears to run both ways. Research on aging connective tissue shows that a stiffer, more fibrotic environment can itself push nearby cells toward senescence. Those cells then produce more of the same stiffening signals, a self-reinforcing loop. Whether this loop operates in muscle and fascia adhesion has not been studied directly. If it does, it would help explain why adhesion often gets worse instead of resolving on its own.
Where shockwave therapy fits
Shockwave therapy does more than mechanically loosen dense tissue. A 2024 systematic review in the International Journal of Molecular Sciences gathered the signaling pathways shockwave activates in fibrotic tissue. Shockwave pulses shift local immune cells (macrophages) from a pro-inflammatory state toward an anti-inflammatory, repair-oriented one. They reduce the excess collagen deposition associated with fibrosis. And they trigger programmed cell death in myofibroblasts, the overactive repair cells most responsible for laying down that excess collagen.
A 2023 animal study in the Journal of Orthopaedic Surgery and Research tested this on joint tissue. Rats with immobilized knees developed joint capsule fibrosis, and shockwave treatment reduced the abnormal collagen buildup and the inflammatory markers driving it. Human data points the same direction. A 2024 retrospective review in Skin Research and Technology of 52 patients with deep fibrosis beneath the skin, mostly after cosmetic procedures or surgery, reported visible improvement in tissue texture and movement after a course of shockwave sessions.
Shockwave and senescence: the preclinical evidence
Until recently, shockwave's antifibrotic effects and cellular senescence were separate research threads. A study published in August 2025 in The American Journal of Sports Medicine connected them in knee osteoarthritis. Researchers examined subchondral bone (the layer just beneath cartilage) in three settings: tissue samples from knee OA patients, a rat model of induced arthritis, and lab-cultured osteoblasts (bone-building cells) under inflammatory stress. In all three, arthritic bone showed more senescence markers than healthy tissue.
The researchers then treated the arthritic rats and the cultured cells with radial shockwave at a carefully tuned dose. Senescence markers dropped substantially, and the abnormal, disorganized bone structure that senescent osteoblasts tend to leave behind was reduced. In the rats, shockwave performed comparably to regular treadmill exercise, one of the better-established non-drug interventions for early knee osteoarthritis.
This is preclinical evidence. The shockwave treatment was tested in rats and cultured cells, not in patients. It does not show that shockwave reverses senescence in people, or that it acts the same way on muscle and fascia adhesion as on subchondral bone in an arthritic knee. Those are different tissues, and the research on each is at a different stage. What it does show is that, in these models, shockwave's effects reached past collagen and local inflammation to the senescent cells themselves.
Why it matters
None of this changes how adhesion is examined or treated day to day. It does suggest why treatment may work at a level deeper than "loosening tight tissue." Shockwave's antifibrotic effects are well documented: less collagen overproduction, more myofibroblast cleanup, calmer local inflammation. The 2025 study adds early evidence that it may also reach the senescent cells involved in joint tissue breakdown. Whether that holds in human muscle and fascia is the next question worth answering.
Sources
- 2025 review in Aging and Disease on tissue fibrosis and cellular senescence. (link)
- 2024 systematic review in the International Journal of Molecular Sciences on signaling pathways activated by shockwave therapy. (link)
- 2023 study in the Journal of Orthopaedic Surgery and Research on joint capsule fibrosis in an immobilized-knee animal model. (link)
- 2024 retrospective review in Skin Research and Technology of 52 patients with deep dermal and subdermal fibrosis. (link)
- Study published in The American Journal of Sports Medicine (August 2025) on radial shockwave therapy and cellular senescence markers in knee osteoarthritis. (link)
